ADC Therapeutics said on Tuesday it had paused enrollment of new patients in a mid-stage study evaluating its drug Zynlonta along with rituximab for treating a type of blood cancer over safety concerns.
https://finance.yahoo.com/news/adc-therapeutics-pauses-enrolment-mid-111707401.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.